Dilmapimod

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameDilmapimod
Drug Alias Name地玛莫德DilmapimodumGW-681323SB-681323GSK-681323
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionP38 γ mitogen-activated protein kinase inhibitors
TargetsP38 γ mitogen-activated protein kinase
Therapy Area/IndicationsInflammationCoronary Artery DiseaseCoronary Disease +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwedenPoland +[15] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsInflammationCoronary Artery DiseaseCoronary Disease +[7] 

Other Information

ATC CodeN/A
Related LinksKEGG